Presidio snags preclinical hep C program for $108M

XTL Biopharmaceuticals is pocketing a $4 million upfront fee and stands to earn another $104 million in milestones after inking a collaboration deal with Presidio Pharmaceuticals for its preclinical hepatitis C program. NS5A is in advanced stages of lead optimization. As part of the license, Presidio obtained rights to several distinct chemical series, including their lead series, which exhibits activity against both the HCV 1a and 1b genotypes. Presidio will assume responsibility for any additional lead optimization, clinical development, and commercialization activities related to the program.

"This license agreement with XTL expands the HCV franchise we created in our ongoing agreements with Stanford and Numerate, and firmly establishes Presidio as a leading developer of medicines for HCV," said Omar K. Haffar, Presidio's president and CEO.

- read the release
- check out the AFX report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.